Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03396341 · ClinicalTrials.gov registry record
Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations
A clinical trial of Genetic Testing and BRCA1/2, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 400
- Enrollment target
- 7
- Study locations
NCT03396341: Recruiting study of Genetic Testing and BRCA1/2, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03396341 is a study of Genetic Testing and BRCA1/2 that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 400 participants, below the 589-participant average among 7 other Genetic Testing trials with a reported enrollment target (32% lower). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03396341, a study of Genetic Testing and BRCA1/2, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to describe how women with BRCA1/2 mutations react to genetic risk modifier testing, and to examine how they make decisions about their healthcare.
Primary Outcome
Hierarchical level modeling (HLM) will be implemented to assess the effect of genetic risk modifier testing on Decisional Conflict Scale score (DCS), allowing for baseline effects via a random intercept.
Conditions Studied
Interventions
- BEHAVIORAL Questionnaires
- OTHER Salvia sample
Study Locations (7)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
Massachusetts
- Dana Farber Cancer Institute (Data Collection Only) - Boston
New Jersey
- Memorial Sloan-Kettering at Basking Ridge - Basking Ridge
Pennsylvania
- Abramson Cancer Center at University of Pennsylvania Medical Center (Data Collection Only) - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2018-01-04 |
| Est. Completion | 2027-01 |
What NCT03396341 shows while recruiting
NCT03396341 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 589-participant average among 7 other Genetic Testing trials with a reported enrollment target (32% lower).
The record links to 2 conditions, with Genetic Testing appearing as the primary indexed condition, and to 2 interventions - of which Questionnaires is the first listed.
NCT03396341 lists 7 locations in 4 states (New York, Massachusetts, New Jersey).
Frequently Asked Questions
What is clinical trial NCT03396341 about?
NCT03396341 is a clinical study titled "Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations". The purpose of this study is to describe how women with BRCA1/2 mutations react to genetic risk modifier testing, and to examine how they make decisions about their healthcare.
What is the current status of trial NCT03396341?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2018-01-04. Estimated completion is 2027-01.
What conditions does trial NCT03396341 study?
This clinical trial studies the following conditions: Genetic Testing, BRCA1/2.
What interventions are being tested in trial NCT03396341?
The interventions under investigation include: Questionnaires (BEHAVIORAL), Salvia sample (OTHER).
Who is sponsoring clinical trial NCT03396341?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03396341 being conducted?
This trial has 7 study locations across Massachusetts, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Testing
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Direct vs Indirect Methods for Cascade Screening
RECRUITING · NA
-
Addressing Genomic Disparities in Cancer Survivors
RECRUITING · NA
-
Universal Genetic Testing for Cancer Risk Reduction
RECRUITING · NA
-
Video Education With Result Dependent dIsclosure
RECRUITING · NA
-
Prospective Registry of Multiplex Testing (PROMPT)
ACTIVE NOT RECRUITING
-
Engaging Adolescents in Decisions About Return of Genomic Research Results
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI